Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel
Our study identified BMI ≥ 25 kg/m<sup>2</sup> as a risk factor and baseline use of mild analgesics as a preventive factor for T-APS development in a real-world GEM + nab-PTX regimen for pancreatic cancer.
Authors
- Yoshito Komatsu (ORCID: https://orcid.org/0000-0002-1570-6802)
- Mitsuru Sugawara (ORCID: https://orcid.org/0000-0001-5350-2950)
- Yoh Takekuma (ORCID: https://orcid.org/0000-0002-4325-0785)
- Yoshitaka Saito (ORCID: https://orcid.org/0000-0001-7159-8650)
Institutions
- Hokkaido University of Science (JP)
- Hokkaido University (JP)
- Hokkaido University Hospital (JP)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1007/s12672-025-03796-2
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 0.00